Impact of Pfizer-BioNTech COVID-19 Vaccination on the Menstrual Cycle
Original Research
P: 99-105
June 2024

Impact of Pfizer-BioNTech COVID-19 Vaccination on the Menstrual Cycle

Bagcilar Med Bull 2024;9(2):99-105
1. University of Health Sciences Turkey Şişli Hamidiye Etfal Training and Research Hospital, Clinic of Gynecological Oncology, İstanbul, Turkey
No information available.
No information available
Received Date: 29.03.2024
Accepted Date: 01.05.2024



To evaluate the effect of Pfizer-BioNTech Coronavirus disease-2019 (COVID-19) vaccination on the menstrual cycle.


This cross-sectional survey study investigated whether Pfizer-BioNTech COVID-19 vaccination affected the menstrual cycle of women who had regular cycles.


One hundred and sixty two of 327 (49.5%) patients who had regular cycles expressed that their menstrual cycle had been affected after vaccination. Univariate analysis revealed a statistically significant relationship between age, body mass index (BMI), parity, smoking, pads per day, intrauterin device (IUD) and the incidence of menstrual change after vaccination. The factors identified by multivariate analysis as being independently related with the menstrual disorders following vaccination were BMI [odds ratio (OR) 1.09, 95% confidence interval (CI) 1.01-1.17, p=0.023], smoking (OR 2.19, 95% CI 1.28-3.78, p=0.005), pads per day (OR 1.42, 95% CI 1.14-1.75, p=0.005) and IUD (OR 5.1, 95% CI 1.99- 13.0, p=0.001).


Approximately half of the participants declared menstrual disorder after vaccination. BMI, smoking, number of pads per day, and IUD were found to be independent risk factors for menstrual changes.

Keywords: COVID-19, menstrual cycle, Pfizer-BioNTech, vaccination


In Turkey, the first Coronavirus disease-2019 (COVID-19) case was identified in March 2020, and the first doses of the Pfizer-BioNTech COVID-19 vaccine were administered in July 2021(1). Previously published studies reported that major and minor menstrual disorders were observed after administration of the Pfizer-BioNTech COVID-19 vaccine (2). Menstrual irregularities, such as heavy bleeding, and shorter or longer cycles have been described in numerous reports of recent research evaluating menstrual disorders connected to severe acute respiratory syndrome-coronavirus-2 immunization (3, 4). In the same sense that irregular menstruation can raise concerns about fertility in women of childbearing age, postmenopausal bleeding can raise fears about endometrial cancer. For this purpose, we designed this study to determine whether the vaccine affected menstrual cycles.

Materials and Methods

This study was approved by Ethics Committee of University of Health Sciences Turkey, Derince Training and Research Hospital, Non-Invasive Clinic Ethics Committee (approval date 27.10.22, institution review board number: 2022-92), patients who received the Pfizer-BioNTech COVID-19 vaccine were informed and included in the study if they gave consent. They were asked to complete a survey form created via Google or face-to-face. Information was given about the study’s voluntary nature, which stated that the findings would not be disclosed to any outside parties. The questionnaire asked about the individuals’ demographics and menstrual patterns (period time, pads per day, pain) of premenopausal patients before and after vaccination (Supplementery File 1). The vaccination had been administered at least 3 months prior to the survey. Patients were asked to provide details about their menstrual cycle following any dose of the Pfizer-BioNTech COVID-19 vaccine. It was also questioned whether postmenopausal patients had bleeding.

Healthy women over the age of 18 years with regular menstrual cycles and without a previous history of abnormal bleeding were included in the study. Patients who were of reproductive age were included if they had at least three cycles of post-pregnancy or post-hormonal contraceptive use.

Exclusion criteria included those with gynecological or hematological illnesses and those using oral contraceptives or the levonorgestrel-releasing intrauterine system (Mirena®).

At first, postmenopausal women were also asked to participate in the survey; however, as none of the participants reported breakthrough bleeding, this group was not included in the analysis of women of reproductive age to prevent misinterpretation.

Statistical Analysis

The Statistical Package for the Social Sciences (SPSS) version 21.0 was used for all statistical analyses. Comparison of categorical variables was performed using exact Fisher’s test, Pearson’s chi-square test, and Yates continuity correction. After the normality of variables was examined by the Kolmogorov-Smirnov test, comparison of continuous variables was performed using an independent-samples t-test or Mann-Whitney U test. P-values <0.05 were considered statistically significant. Data are expressed as mean ± standard deviation or median and interquartile range for continuous variables, and ​​absolute numbers and percentages for categorical values. Multivariate logistic regression was performed for variables that were significant in the univariate analysis. The odds ratio (OR) was supported by confidence intervals and p-values.


Throughout the study, 392 questionnaires were completed. Four were excluded because of incomplete answers, 13 of them used oral contraceptive drugs, and 6 of them stated that they did not have regular periods. Twenty-three responders in all were excluded from the research, and with 369 participants overall, the study was finished. Forty-two of them were in the postmenopausal period. None of the postmenopausal women had postmenopausal bleeding following vaccination. The mean age of postmenopausal women was 56.3±7.2 years (range 45-68).

Excluding the postmenopausal group, 327 women of reproductive age were evaluated for statistical analysis. The mean age was 36.3±7.8 years (range 18-49). One hundred sixty-five of 327 women (51.5%) reported no change after being vaccinated. One hundred sixty-two (49.5%) women who had regular cycles stated that their menstrual cycle had been affected after vaccination. Sixty-nine women had unusually heavy flows after vaccination, and 75 had longer bleeding. Fourty-eight of these group of women both experienced heavy and longer bleeding. Eighteen women experienced breakthrough bleeding. Fifty-seven women had decreased menstrual bleeding, 33 had a shorter menstrual bleeding, and 21 of these experienced both decreased and shortened bleeding. Eighteen (5.5%) women expressed that they had menstrual cycles in longer time intervals, while 6 (1.8%) women had menstrual cycles more often. Dysmenorrhea developed in 15 of 178 patients (8.4%) who had not previously complained of dysmenorrhea.

There were no differences in the reported onset of new menstrual-related symptoms among patients who received one, two, three, or four vaccination doses (p=0.096). It was not associated with previous COVID-19 disease (p=0.493).

Univariate analysis revealed a statistically significant relationship between age, body mass index (BMI), parity, smoking, pads per day, intrauterine device use, and the incidence of menstrual change after vaccination (Table 1). It was found that the age of those who had menstrual changes was older than that of those who did not (37.8±7.4 vs. 34.7±7.9, p<0.001) but it was not found statistically significantly by multivariate analysis (p=0.187). The factors identified by multivariate analysis as being independently related with the menstrual disorders following vaccination were BMI [OR 1.09, 95% confidence interval (CI) 1.01-1.17, p=0.023], smoking (OR 2.19, 95% CI 1.28-3.78, p=0.005), pads per day (OR 1.42, 95% CI 1.14-1.75, p=0.005) and intrauterin device (OR 5.1, 95% CI 1.99-13.0, p=0.001) (Table 2).

There was no statistically significant difference in age between the group that experienced an increase in bleeding and the group that experienced a decrease (39.2±5.6 vs. 37.5±8.6, p=0.217).

Of the 162 patients with menstrual disorders, 45 (27.8%) contacted a doctor, no issues found in 36 of them. Ovarian cysts were detected in 3 patients and premenopausal signs were found in 6 patients.


Menstruation is an inflammatory process. Natural killer cells, macrophages, mast cells, neutrophils, dendritic cells, and T-cells are all drawn in throughout the menstrual cycle and contribute to the destruction and regeneration of the functional endometrium. The vaccination-induced systemic immune response may affect this inflammation (5). In addition, immune thrombocytopenia, in which both thrombotic and hemorrhagic events are observed following vaccination, is thought to occur via a heparin-induced thrombocytopenia-like mechanism (6, 7). Menstrual alterations may be explained by immune-related procoagulative and pro-inflammatory states. Consistent with this, the recent research involving healthy participants found a link between receiving the COVID-19 vaccination and alterations in menstrual flow (3, 8, 9).

According to a web-based survey, 42% of people with regular menstrual cycles bled more heavily than usual, while 44% reported no change after being vaccinated. In addition, 66% of postmenopausal people reported breakthrough bleeding. They discovered a strong correlation between age and increased/breakthrough bleeding (3).

Up to 66% of the participants in another study reported experiencing new or worsening menstrual-related symptoms in the first cycle following vaccination; these changes were noted to be temporary after 2 months (10).

In the current study, various menstrual changes were observed. In addition to the observation of heavy and prolonged bleeding, the number of people reporting decreased and infrequent menstrual patterns was also significant. However, no patient experienced postmenopausal bleeding.

COVID-19-infected women experienced temporary menstrual abnormalities, primarily longer periods and decreased volume, as well as shortened or disordered menstrual cycles and increased volume, in line with vaccinated women (11, 12). It was not the purpose of our study to investigate menstrual changes following COVID-19 disease. However, no relationship was found between history of COVID-19 disease and menstrual irregularities observed among vaccinated women.

In the current study, although the high ratio of being affected by the vaccine (n=162, 49.5%), the low rate (n=45, 27.8%) of consulting a doctor actually suggests that the complaints were either vague or temporary.

Study Limitations

The study’s limitations include its small sample size, the subjectivity of the responses because there is variation in women’s normal periods, and the possibility that participants’ preconceived notions about the vaccine due to misinformation and anti-vaccine activists’ discourse may influence the answers. Myths of vaccines regarding fertility and reproduction are especially powerful because they afflict a huge portion of the population.

It is important to show whether these changes can be linked to vaccination itself, clarify the duration of such changes, and begin to understand the mechanism of these vaccine-related menstrual changes. Therefore, it is necessary to quantify the prevalence of menstrual changes after vaccination in comparison with women vaccinated against other COVID-19 vaccines or unvaccinated control groups. By providing a more comprehensive understanding and open communication about potential menstrual changes related to vaccines, this research can help decrease vaccine hesitancy among menstruating individuals.

To assess the association between vaccination and menstrual alterations more precisely, a prospective evaluation before and after vaccination was required. Considering the chaos and anxiety that the COVID-19 era brought forth, this could not be planned. This study design can be conducted more systematically and prospectively in case similar situations occur in the future.


The following vaccination, approximately 50% of individuals reported having menstrual problems. It was found that BMI, smoking, IUDs, and pre-vaccination quantity number of pads used daily were independent risk factors for disordered menstruation.

Acknowledgments: I would like to thank our Gynecological Oncology Clinic Nurse Demet Tuğ for helping to collect data.


Ethics Committee Approval: This study was approved by Ethics Committee of University of Health Sciences Turkey, Derince Training and Research Hospital, Non-Invasive Clinic Ethics Committee (approval date 27.10.22, institution review board number: 2022-92).

Informed Consent: Informed consent was obtained.

Financial Disclosure: The author declared that this study received no financial support.


Al-Ali D, Elshafeey A, Mushannen M, Kawas H, Shafiq A, Mhaimeed N, et al. Cardiovascular and haematological events post COVID-19 vaccination: A systematic review. J Cell Mol Med 2022;26(3):636-653.
Lee KMN, Junkins EJ, Luo C, Fatima UA, Cox ML, Clancy KBH. Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination. Sci Adv 2022;8:eabm7201.
Laganà AS, Veronesi G, Ghezzi F, Ferrario MM, Cromi A, Bizzarri M, et al. Evaluation of menstrual irregularities after COVID-19 vaccination: Results of the MECOVAC survey. Open Med (Wars) 2022;17(1):475-484.
Berbic M, Fraser IS. Immunology of normal and abnormal menstruation. Womens Health (Lond) 2013;9(4):387-395.
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021;384(22):2092-2101.
Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 2021;96(5):534-537.
Edelman A, Boniface ER, Benhar E, Han L, Matteson KA, Favaro C, et al. Association Between Menstrual Cycle Length and Coronavirus Disease 2019 (COVID-19) Vaccination: A U.S. Cohort. Obstet Gynecol 2022;139(4):481-489.
Baena-García L, Aparicio VA, Molina-López A, Aranda P, Cámara-Roca L, Ocón-Hernández O. Premenstrual and menstrual changes reported after COVID-19 vaccination: The EVA project. Womens Health (Lond) 2022;18:17455057221112237.
Muhaidat N, Alshrouf MA, Azzam MI, Karam AM, Al-Nazer MW, Al-Ani A. Menstrual Symptoms After COVID-19 Vaccine: A Cross-Sectional Investigation in the MENA Region. Int J Womens Health 2022;14:395-404.
Li K, Chen G, Hou H, Liao Q, Chen J, Bai H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online 2021;42(1):260-267.
Demir O, Sal H, Comba C. Triangle of COVID, anxiety and menstrual cycle. J Obstet Gynaecol 2021;41(8):1257-1261.
2024 ©️ Galenos Publishing House